〔Abstract〕 Objective To investigate the value of combined stool syndecan-2(SDC2) and tissue factor pathway inhibitor 2(TFPI2) gene methylation testing in the early screening of colorectal cancer. Methods 106 patients with colorectal cancer(colorectal cancer group), 75 patients with advanced adenoma(advanced adenoma group) and 35 patients with non-advanced adenoma(non-advanced adenoma group) were selected as study subjects, and 153 patients with other gastrointestinal disorders and 182 patients with negative colonoscopy results during the same period were selected as the control group. The quantitative methylation-specific PCR(qMSP) method was used to detectSDC2andTFPI2gene methylation in the stool specimens of all subjects. The sensitivity and specificity of the combinedSDC2andTFPI2gene methylation assay for the detection of colorectal cancer and adenoma were evaluated using colonoscopy and pathology results as the gold standard. Results Among 106 patients with colorectal cancer, the sensitivity of combined methylation test was 93.4%; among 75 patients with advanced adenoma, the sensitivity of combined methylation test was 62.7%; among 35 patients with non-advanced adenoma, the sensitivity of combined methylation test was 34.3%; the specificity of the combinedSDC2andTFPI2gene methylation test for colorectal cancer and adenoma screening was 94.6%. Conclusion The combinedSDC2andTFPI2gene methylation test has high sensitivity for colorectal cancer and its early lesions, and it also maintains high specificity.